SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Howe who wrote (1168)9/16/1998 11:39:00 PM
From: RCMac  Read Replies (1) of 10280
 
CEO Tim Barberich's brief CNBC appearance this morning had no major news for those who follow the company, but a few details were new, at least to me:

(1) DCL, the ICE for Schering's Claritin, is already in Phase III, with FDA approval expected in about 18 months, or no more than 2 years. (At the May 27 annual meeting he had said that Schering was making an all-out effort to get DCL on the market long before generic competition would arise at Claritin's patent expiration in 2002, spending $200 million this year alone, etc.; it's good news that they're making fast progress.)

(2) Levalbuterol (Xopenex) final FDA approval expected within the month.

(3) Allegra sales will be about $800 million this year (compared to 1997 sales of, I believe, about $600MM).

(4) SEPR now has seven of its ICE's in clinical trials, three of them in Phase III.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News